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Abstract
Purpose To analyse safety and efficacy of treatment based on ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in 
the sub-group of GT1 patients older than 65 years.
Methods We collected data extracted from the ABACUS compassionate-use nationwide Italian programme, in patients with 
cirrhosis due to hepatitis C virus (HCV) Genotype-1 (GT1) or 4 and at high risk of decompensation. GT1-HCV-infected 
patients received once-daily ombitasvir/paritaprevir, with the pharmacokinetic enhancer ritonavir (25/150/100 mg) and twice-
daily dasabuvir (250 mg) plus Ribavirin (RBV) (OBV/PTV/r + DSV + RBV) for 12 (GT1b) or 24 (GT1a) weeks. Endpoints 
were to evaluate safety and efficacy, the latter defined as HCV RNA negative 12 weeks after the end of treatment (SVR12).
Results Patients who suffered any adverse event (AE) were 74/240 (30.8%); 13/240 (5.4%) discontinued the treatment. A 
multivariate analysis found albumin < 3.5 g/dL (OR 2.04: 95% CI 1.0–4.2, p < 0.05) and hypertension (OR 4.6: 95% CI 
2.3–9.2, p < 0.001) as variables independently associated with AE occurrence. The SVR12 was 95% (228/240). Multivariate 
analysis identified baseline bilirubin < 2 mg/dL (OR 4.9: 95% CI 1.17–20.71, p = 0.029) as the only variable independently 
associated with SVR12.
Conclusion Our findings suggest that OBV/PTV/r + DSV + RBV is safe and effective in real-life use in patients with com-
pensated cirrhosis, HCV-GT1 infection, and age over 65.
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Introduction
In Italy, liver cirrhosis (LC) and hepatocellular carcinoma 
(HCC) are the two main causes of death due to liver dis-
eases. These two serious conditions caused, according to 
the last available data, 8071 deaths from LC and 10,116 
from HCC [1]. Several Italian studies over the years have 
shown that, at least in 65% of cases, these two diseases 
are linked to HCV chronic infection [2–5]. In addition, the 
HCV infection is a major cause of liver transplantation in 
Italy [6–8].
For this reason, with the institutional endorsement of 
the Italian Medicines Agency (AIFA-Agenzia Italiana 
del Farmaco), we did the AIFA-based AISF (Associazi-
one Italiana per lo Studio del Fegato) Compassionate 
Use Study (ABACUS) to provide pre-approval access 
to ombitasvir, paritaprevir, with the pharmacokinetic 
enhancer ritonavir, ± dasabuvir + ribavirin (OBV/PTV/
r± DSV + RBV) for HCV Genotype 1 (GT1) and 4 infec-
tion at high risk of decompensation. This combination, at 
the time of the beginning of this study, had not yet been 
authorized for reimbursement by the Italian National 
Health System, but had already shown a positive risk–ben-
efit ratio in the registration studies [9–12]. The availability 
of real-world data gives the opportunity to evaluate the 
safety and efficacy of the OBV/PTV/r ± DSV + RBV com-
bination even in a sub-group of patients, such as elderly 
subjects, generally underrepresented in phase III trials, 
especially when affected by advanced fibrosis or cirrhosis. 
Based on these considerations, the present study reports 
the analysis of data from patients with cirrhosis GT1 
over the age of 65 years, extracted from the group of 762 
included in the already published ABACUS Study [13].
Methods
Design of the study
ABACUS was a prospective, longitudinal, observa-
tional study and not a clinical trial. The enrolment 
started on March 17, 2014 till May 28, 2015 when OBV/
PTV/r + DSV received the marketing approval. The study 
has been described in detail elsewhere [13]. One hundred 
and seventy-six referral centres specialized in hepatology, 
located in various parts of Italy and active in the AISF, 
participated in the ABACUS study. As ABACUS was 
a study to test the drug in compassionate use, a sample 
size was not calculated. Patients received once-daily co-
formulated OBV/PTV/r (25/150/100 mg) and twice-daily 
DSV (250 mg) for 12 (GT 1b) or 24 weeks (GT 1a) plus 
weight-based RBV (1000 or 1200 mg according to the 
RBV label). The DAAs were provided by AbbVie (Cam-
poverde, Italy) as the funding source. Management of side 
effects was not standardized by protocol. In particular, in 
case of anaemia, the centres were completely free to use 
either blood transfusion or erythropoietin or reduce the 
dose of RBV. Therefore, this study represents a real clini-
cal practice in the management of antiviral therapy in Italy 
and provides information that usually the trials are not able 
to give because of the very selective enrolment criteria. 
This study was conducted in compliance with the Interna-
tional Conference on Harmonisation guidelines, the rules 
formulated by the Declaration of Helsinki and the appli-
cable regulations at each study site. Local ethics approval 
was obtained at each site. All patients provided a written 
consent to participation in the study and gave permission 
to use their data for scientific purposes anonymously.
As with all studies where the drug is administered for 
compassionate use, the centres were free to organize clini-
cal and laboratory features of the patients under their care. 
Investigators did laboratory assessments in their hospital 
lab, including international normalized ratio (INR), albumin 
concentration, bilirubin concentration, alanine aminotrans-
ferase (ALT) concentration, and haemoglobin concentration, 
at baseline, at treatment weeks 2 and 4, every 4 weeks during 
treatment thereafter, and at week 12 after treatment. HCV 
RNA was assessed at baseline, in the fourth week of treat-
ment, at the end of treatment, and in week 12 post-treatment. 
We recorded data on adverse events (AEs) throughout the 
study. Patient visits and follow-up, as well as laboratory test-
ing, were done according to the sites’ local standards. Labo-
ratory and safety data were reported on an ongoing basis on 
a spreadsheet to the principal investigator.
Because safety was one of the primary purposes of this 
analysis, this aspect was checked and recorded carefully by 
all the centres. Any type of AE was reported in the results. 
AEs were graded according to Common Terminology Cri-
teria for Adverse Events (CTCAE) Version 4.0.
The efficacy was judged by the proportion of patients 
who, after 12 weeks from discontinuation of therapy, showed 
a serum HCV RNA below the detection limit set at < 25 IU/
mL (SVR12). Patients who did not become HCV RNA nega-
tive during treatment, or again became HCV RNA positive 
during the follow-up, were considered non-responders or 
relapsers.
Patients
Inclusion criteria for the enrolment in this compassionate-
use prospective programme were the following: active 
Hepatitis C infection by GT1 or GT4 (only patients infected 
from the GT1 are considered in the present analysis) and 
compensated cirrhosis at high risk of decompensation. 
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High risk of decompensation was defined as clinical fea-
tures suggestive of rapidly progressive fibrosis or impending 
decompensation (e.g. a rapid decline in platelets, albumin 
concentration, or both) or with previous signs or history of 
decompensation, or with rapid progression from histologi-
cally or clinically proven chronic HCV infection without cir-
rhosis to clinically diagnosed cirrhosis. All patients were in 
Child–Turcotte–Pugh (CTP) Class A cirrhosis at the time of 
enrolment, but those with a history of decompensation were 
not excluded. Diagnosis of cirrhosis was made by histology 
from a liver biopsy, and/or  Fibroscan® result > 14.6 kPa, 
and/or a platelet count < 100 × 109/L, and/or the presence of 
oesophageal varices. Patients enrolled were treatment naïve, 
treatment non-responders, relapsers or intolerant to therapy 
based on pegylated interferon plus ribavirin. Subjects with 
HBV- or HIV-coinfection were not included.
Statistical analysis
As with all compassionate studies it was not appropriate to 
calculate a sample size. All those who met the established 
criteria had the right to make use of the drug before it came 
on the market.
Efficacy data were analysed for the intention-to-treat 
(ITT) population, defined as all enrolled patients who 
received at least one dose of study drug. All main base-
line demographic and patient-related qualitative/quantita-
tive characteristics are expressed as percentage or as mean 
(± standard deviation) or as median (range). The only two 
end-point-dependent variables in the study were safety 
(defined as the percentage of subjects with an AE of any 
grade) and efficacy (defined as a proportion of patients with 
SVR12). Comparison between each qualitative variable and 
dependent variables was made using the Chi-square (χ2) test 
or Fisher’s exact test, if necessary. Comparison between each 
continuous variables and dependent variables was made 
using the t test or Mann–Whitney test when indicated. In 
both cases, it was used a significance level defined as p value 
less the 0.05 and 95% confidence interval (CI) of the differ-
ences. All baseline characteristics that were associated with 
AEs or SVR12 at univariate analysis were considered as pos-
sible independent predictors in the logistic regression model 
considering AEs or SVR12 as dependent variables. A mul-
tivariate analysis was performed using logistic regression 
with a stepwise backward method. The variables entered at 
the beginning of the procedure that were quantitative were 
categorical according to clinical criteria and were: gender, 
age (< 70 vs ≥ 70 years); albumin (ALB) < 3.5 vs ≥ 3.5; total 
bilirubin (BilT) < 2 vs ≥ 2. The CTP class was not inserted 
because 2 of the 5 constituent parameters were absent in the 
initial case series (ascites, encephalopathy). Therefore, we 
decided to consider the quantitative parameters separately: 
ALB, BilT and INR.
Analysis was performed using statistical software pack-
age SPSS for windows, version 15.0. Chicago, SPSS Inc.
Role of the funding source
The funder of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report. All authors approved the manuscript and had the 
final responsibility for the decision to submit the data for 
publication.
Results
Patients
From the 762 patients, all over the age of 18, enrolled in the 
ABACUS study, we extrapolated and analysed 240 patients 
over 65 years old (31.5%), infected by GT1. We excluded 
patients infected with GT4 because the number was too 
small, three patients only.
The main demographic and liver disease characteristics 
are presented in Table 1.
In the period between enrolment and start of treat-
ment, a change in CTP class, from A to B, was found in 
16 patients (6.7%) that were included in the analysis; they 
had a mean baseline (SD) age of 71.9 (5.1); male sex in 
50% (8/16); oesophageal varices in 62.5% (10/16); ascites in 
12.5% (2/16); values of serum albumin < 3.5 g/dL in 68.8% 
(11/16), total bilirubin > 2 mg/dL in 50% (8/16), thrombo-
cythemia < 100 × 109/L in 50% (8/16); one of them had a 
prior episode of hepatic decompensation, 12 patients (75%) 
were previously treated with the antiviral therapy; 7 patients 
(43.8%) had basal HCV RNA > 1 × 106 IU/mL.
Seventy patients had comorbidities (29.2%): hyperten-
sion 45 (18.8%), diabetes 16 (6.7%), thyroid dysfunction 13 
(5.4), cardiovascular disease 11 (4.6%), psychiatric disorders 
8 (3.3%), and lymphoma 1 (0.4%).
Safety
During treatment, patients who had an AE of any grade were 
74/240 (30.8%): 27/102 (26.5%) for females and 47/138 
(34.1%) for males; this difference was not statistically sig-
nificant (95% CI − 4.3 to 18.8%, p = 0.21).
As it is generally believed that the older subjects are a cat-
egory more exposed to AEs, we have compared the onset of 
AEs in individuals younger than 70 years against those with 
age of 70 and over. The difference found was not statistically 
significant (95% CI − 7.6 to 15.5, p = 0.49). Thirteen patients 
(5.4%) discontinued therapy because of AEs.
Table 2 shows in detail all AEs recorded during the study. 
The most frequent AE was anaemia (12.1%), in most cases 
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mild, and only in four cases (1.6%) severe enough (< 8 g/dL) 
to require transfusions (Fig. 1a). The second most frequent 
AE was the hyperbilirubinemia (6.2%), in five cases (2.1%) 
severe (> 5 mg/dL), but only one interrupted the therapy 
for this reason (Fig. 1b). The third more frequent AE was 
asthenia (5.4%), in all, but one, cases of mild degree. The 
other event that occurred in at least 10 cases was pruritus 
(4.6%), only in one case was it severe but treatment was not 
interrupted and he got SVR12.
Three patients decompensated during therapy: two due 
to ascites and one to encephalopathy (1.25%). Those with 
ascites (both in the fourth week of treatment) stopped ther-
apy; while the one who developed mild encephalopathy, 
Table 1  Baseline characteristics of patients (n = 240)
a BMI missing 42 (17.5%)
b Estimated glomerular filtration rate calculated by CKD-EPI
Male sex, n (%) 138 (57.5)
Age (years), mean (SD) 70.4 (3.8)
 Age > 69 years, n (%) 125 (52.1)
BMIa (kg/m2), mean (SD) 25.6 (3.6)
 BMI < 30 (kg/m2), n (%) 178 (74.2)
Creatinine (mg/dL), mean (SD) 0.76 (0.18)
eGFRb (mL/min/1.73 m2), mean (SD) 85.9 (17.7)
eGFR (mL/min), n (%)
 ≥ 90 114 (53.5)
 60–89 75 (35.2)
 < 60 24 (11.3)
ALT (IU/L), mean (SD) 87.6 (55.3)
Total bilirubin (mg/dL), mean (SD) 1.12 (0.59)
International normalized ratio, mean (SD) 1.15 (0.26)
Albumin (g/dL), mean (SD) 3.82 (0.45)
Platelets (× 109/L), mean (SD) 113 (54)
Child–Turcotte–Pugh class B (%) 16 (6.7)
MELD score ≥ 10 (%) 66 (27.5)
Fibroscan® (kPa), mean (SD) 20.85 (10.0)
Esophageal varices (%)
 Absent 134 (55.8)
 Present 74 (30.8)
 Unknown 32 (13.3)
HCV genotype (%)
 1 (unknown subtype) 5 (2.1)
 1a 16 (6.7)
 1b 219 (91.3)
Baseline HCVRNA > 106 IU/mL (%) 128 (53.3)
Treatment naïve, n (%) 66 (27.5)
History of previous liver decompensation (%) 1 (0.42)
Ascites at baseline (%) 2 (0.83)
Portal thrombosis (%) 2 (0.83)
Transplanted (%) 4 (1.7)
Comorbidities (any) (%) 70 (29.2)
Comorbidity (%)
 Arterial hypertension 45 (18.8)
 Diabetes 16 (6.7)
 Cardiovascular disease 11 (4.6)
 Thyroid dysfunction 13 (5.4)
 Psychiatric disorders 8 (3.3)
 Lymphoproliferative disorders 1 (0.4)
Table 2  Adverse events recorded during the study
Mild Moderate Severe Total
Anaemia 19 6 4 29
Hyperbilirubinemia 9 1 5 15
Asthenia 12 1 0 13
Pruritus 8 2 1 11
Insomnia 6 1 0 7
Arthromyalgia 4 2 1 7
Diarrhoea 2 1 0 3
Pneumonia 0 0 3 3
Dizziness 3 0 0 3
Ascites 2 0 0 2
Atrial fibrillation 0 1 1 2
Glossitis 2 0 0 2
Urinary tract infection 1 0 1 2
Nausea 2 0 0 2
Transient eGFR decrease 1 0 0 1
Anxiety 1 0 0 1
Dental abscess 1 0 0 1
Dermatitis 0 1 0 1
Dyspnoea 1 0 0 1
Epigastralgia 0 1 0 1
Epistaxis 1 0 0 1
Encephalopathy 1 0 0 1
Hepatocellular carcinoma 0 0 1 1
Hepatitis flare 0 1 0 1
Transient ischemic attack 0 1 0 1
Arterial hypertension 1 0 0 1
Hypokaliemia 0 1 0 1
Arterial hypotension 1 0 0 1
Lack of appetite 1 0 0 1
Lymphoma 0 0 1 1
Ocular myasthenia 0 0 1 1
Heart palpitations 1 0 0 1
Rash 1 0 0 1
Herpes zoster 1 0 0 1
Glycaemic decompensation 0 0 1 1
Sweating 1 0 0 1
Tachycardia 1 0 0 1
Thoracic pain 0 0 1 1
Cough 1 0 0 1
Lichen planus ulcers 1 0 0 1
Total 86 20 21 127
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continued the therapy. All these patients obtained the 
SVR12.
A group of patients needed hospitalization for: pneumo-
nia three cases, atrial fibrillation 1, hepatic encephalopathy 
1, lymphoma 1, glycaemic decompensation 1. In one case, 
a HCC was found and this had not been detected prior to 
the start of therapy; but may have been present as the last 
ultrasonography of the abdomen was performed more than 
1 year before.
Two patients (0.8%) died. The first patient died in 
the 12th week of starting treatment for pneumonia and 
hepatopulmonary syndrome. He was a 68-year-old man, 
treatment naïve and had a prior episode of hepatic decom-
pensation before being enrolled. The other patient who 
died was a 66-year-old male, treatment naïve, discontin-
ued in the eighth treatment week due to the appearance 
of signs of lymphoma and who died for this reason in the 
20th week after starting therapy.
Patients in CTP Class B had more AEs (9/16, 56.3%) 
compared to those in CTP Class A (65/224, 29%); this differ-
ence (27.2%) was statistically significant (95% CI 3.3–48.6, 
p = 0.02); however, their distribution and grade were not dif-
ferent from the CTP class A patients.
As for safety, in most cases there was no worsening 
of eGFR. Patients who at baseline had reduced eGFR 
(< 50 mL/min) were few (11/240, 4.6%), and they had no 
deterioration during the treatment (Fig. 1c).
A univariate analysis was conducted to verify the asso-
ciation between any AE and major demographic/clinical 
baseline variables (age, gender, BMI, previous treatments, 
comorbidities) and bilirubin, albumin, INR, platelet count, 
haemoglobin, eGFR, CTP Class and MELD score.
The only variables associated with the presence of at least 
one AE were: albumin less than 3.5 g/dL, CTP Class B and 
the presence of hypertension as comorbidity. The following 
baseline characteristics were found to be independently asso-
ciated in multivariate logistic regression analysis: albumin 
< 3.5 g/dL (OR 2.04: 95% CI 1.0–4.2, p < 0.05) and hyper-
tension (OR 4.6: 95% CI 2.3–9.2, p < 0.001).
In conclusion, about the correlation between AEs and 
therapy, only in the case of anaemia and hyperbilirubinemia, 
the event was connected, with reasonable certainty, to the 
use of ribavirin in the therapeutic schedule. As for the other 
AEs indicated as “severe” in Table 2, none of them was 
certainly ascribed by researchers to the use of study drugs.
Efficacy
The overall SVR12 rate was 95% (228/240) among patients 
who received OBV/PTV/r + DSV + RBV therapy for 12 
or 24 weeks. The SVR12 was similar in patients with age 
< 70 years (110/115, 96%) compared to those ≥ 70 (118/125; 
94%) (difference = 2%: 95% CI 5–7%, p = 0.66). Moreover, 
both in males and females, in patients with high or low 
BMI and in naive patients or PEG-IFN experienced there 
was no statistically significant difference as for SVR. As 
far as the viral variables are concerned, GT1a and 1b, and 
a viral load statistically significant differences were not 
found in those who achieved the SVR12: in patients with 
basal HCV RNA < 1 × 106 IU/mL (104/112, 93%) versus 
those with HCV RNA ≥ 1 × 106  IU/mL (124/128, 97%) 
(difference = 4%: 95% CI − 2.1 to 10.5, p = 0.19); in GT1b 
infection (209/219; 95%) versus those with GT1a (15/16; 
94%) (difference = 1%: 95% CI − 4.6 to 23.9%, p = 0.76) 
and not-typeable GT1 (4/5; 80%) (difference = 15%: 95% 
CI − 1.3–57.9%, p = 0.59) (Fig. 2).
A higher percentage of SVR12 was found in patients 
with a better hepatic functional reserve, CTP Class A 
(215/224, 96%), compared to those with CTP Class 
B (13/16; 81%) (difference = 15%: 95% CI 2.1–39.1, 
p = 0.04); in patients with albumin ≥ 3.5 g/dL (187/194, 
96%) versus albumin < 3.5 g/dL (41/46, 89%) (differ-
ence = 7%: 95% CI 0.2–19.8, p = 0.04); in patients with bil-
irubin < 2 mg/dL (210/219, 96%) versus bilirubin ≥ 2 mg/
Fig. 1  Box plots for haemoglobin, bilirubin and eGFR levels during 
treatment and post-treatment week 12 (PT WEEK 12). a Haemoglo-
bin at baseline vs haemoglobin at PT WEEK 12, p = 0.012. b Bili-
rubin at baseline vs bilirubin at PT WEEK 12, p < 0.001. c eGFR at 
baseline vs eGFR at PT WEEK 12, p = 0.024
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dL (18/21, 86%) (difference = 10%: 95% CI 1.3–31.3, 
p = 0.04). For model for end-stage liver disease (MELD) 
score, SVR12 rates were similar among patients with the 
MELD score ≥ 10 (61/65, 94%) in comparison with the 
MELD score < 10 (167/175, 95%) and this difference was 
not statistically significant (difference = 1%: 95% CI − 4.0 
to 10.5, p = 0.74) (Fig. 3).
Moreover, there was no statistical difference in patients 
with platelet count ≥ 100 × 109/L (122/127, 96%) vs platelet 
count < 100 × 109/L (106/113, 94%) (difference = 2%: 95% 
CI − 4.5 to 7.6%, p = 0.63).
Among patients who achieved SVR12, markers of liver 
function, including increased albumin (p < 0·001) and 
decreased bilirubin (p < 0.001) significantly improved in 
post-treatment week 12 compared with baseline, while this 
result did not occur for INR values (p = 0.57).
A multivariate logistic regression analysis was used 
to identify factors associated with SVR12; this analysis 
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identified that baseline bilirubin < 2 mg/dL was the only 
variable independently associated with SVR12 (OR 4.9: 
95% CI 1.2–20.7, p = 0.02).
No virological breakthrough occurred during the 
treatment. Twelve patients (5%) including relapsers 
(3/240 = 1.3%) did not respond to the treatment. Their 
median age was 70 (range 66–83); 83.3% male, 83% GT1b 
with BMI less than 24 in 54.5%. This group of patients 
had the following baseline median (range) or occurrence 
number/total number (%): Hb 12.7 g/dL (9.9–15.1); biliru-
bin 1.00 mg/dL (0.30–3.20); albumin 3.8 g/dL (2.5–5.1); 
INR 1.10 (0.80–1.40); platelets count 80 × 109/L (49–169); 
ALT 73 IU/L (18–443); eGFR 90 mL/min (61–111); fibro-
scan 18 kPa (12–48); HCV RNA > 1 × 106 IU/mL in 4/12 
(33.3%); MELD > 10 in 4/12 (33.3%); CTP Class B in 3/12 
(25%); oesophageal varices 6/12 (50%); ascites 2/10 (20%); 
presence of cryoglobulins 3/12 (25%); treatment naive 6/12 
(50%); comorbidities 6/12 (50%); arterial hypertension 3/12 
(25%).
Discussion
This analysis is part of a prospective compassionate-use 
nationwide programme including only patients infected 
with HCV GT1, with cirrhosis and over 65 years of age. 
To our knowledge, this is one of the largest real-life stud-
ies dealing with cirrhotic of old age treated with OBV/
PTV/r + DSV + RBV. The results, in general, surprised us, 
considering, above all, that the enrolled patients had at that 
time no therapeutic alternatives and had an advanced liver 
disease. Indeed, our results showed that in patients over 
65 years old with compensated cirrhosis this treatment is 
well tolerated. It is remarkable that a population, always 
considered “special” or “difficult-to-treat” because of the 
risk of hepatic decompensation on treatment, had a relatively 
low percentage of any adverse events (74/240 = 30%), an 
amount not different from other studies that used the same 
type of treatment in non-cirrhotic patients (31.9%) [13] or 
using many different DAAs (65%) [14, 15]. However, in a 
review article, specifically dedicated to the elderly infected 
with HCV, the occurrence of AEs was quite high (87%), and 
in those receiving ribavirin even higher (93.9%), although 
the severity was in most cases mild–moderate [16], as has 
been reported in the present study (Table 2). The most com-
mon AE was anaemia, which was severe only in 1.6% of 
cases. Hyperbilirubinemia was the second most frequent 
AE, severe in 2.1% of cases. In one case, the therapy was 
interrupted. Anaemia and hyperbilirubinemia (mostly 
unconjugated) could be related to the use of ribavirin which 
notoriously can cause haemolysis; but hyperbilirubinemia 
could also be due to the inhibition of bilirubin transport 
due to paritaprevir [17]; in any case, bilirubin returned to 
baseline during or shortly after the end of therapy. All other 
AEs were mild and did not hinder the normal schedule of 
therapy. Eight patients (3.3%) needed hospitalization and 
two of them (0.8%) died: one because of the hepatopulmo-
nary syndrome and the second because of lymphoma. Dur-
ing therapy three patients developed decompensation (two 
ascites, one encephalopathy). However, this finding is not 
unexpected, bearing in mind that the patients enrolled were 
cirrhotic and at risk of liver decompensation. This was the 
condition without which the patients could not be included 
in this study, and for this category of patients an annual risk 
of 6.37% of spontaneous liver decompensation is reported 
[18]. The percentage of hepatic decompensation in our study 
is lower, but it must be said that the follow-up of our patients 
is 6 months only.
This study provided other relevant information concern-
ing renal function. In fact, there was no deterioration, even 
in the few patients with eGFR reduced at the baseline. When 
we compared the AE data of this study with other similar 
studies of real life [19, 20], we noticed that in many of them 
the percentages of some subjective symptoms (tiredness 
and headache above all) were present in significantly higher 
percentages than those recorded in our patients. How can 
this difference be explained, considering that patients in the 
ABACUS study were all in cirrhosis and at the same time at 
risk of decompensation? A possible explanation lies in the 
high motivation that these patients had regarding therapy 
and that could, therefore, be the reason why they tend to 
better tolerate subjective disturbances.
As for the efficacy, the percentage of SVR12 obtained in 
this group of patients (advanced cirrhosis, age > 65, many 
non-responders/relapsers to previous antiviral treatments) 
was high (95%). Analysing similar real-life studies where 
data for patients of the same age were reported, though 
mainly younger and with less hepatic impairment, the 
percentages of SVR12 obtained with this treatment were: 
96.6% [12]; 88.3% [15]; 95% [16]; 94.7% [19]; 91.2% [20]; 
97.9–96.2 [21]. An element that should be stressed, in our 
study, is that a liver with reduced functional capacity at 
baseline significantly reduces the likelihood of SVR12. It is 
very important to note that this study showed that patients 
belonging to the CTP Class A had a significantly higher 
SVR12 than patients in Class B. In particular, having an 
albumin < 3.5 g/L or bilirubin > 2 mg/dL significantly 
reduces the possibility of SVR12.
Even patients with MELD < 10 had a better SVR12, but 
this difference was not found to be statistically significant. 
If we combine these data with the results provided by multi-
variate analysis, we can assume that the liver functional state 
is the most important predictor of virological response in 
this patient’s category. According to the EASL recommenda-
tions, “the combination of ritonavir boosted paritaprevir and 
ombitasvir with or without dasabuvir is not recommended 
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for patients with moderate hepatic impairment (CTP Class 
B) and is contraindicated in patients with severe hepatic 
impairment (CTP Class C)” [22]; AISF also suggests that 
this combined therapy is not recommended in advanced cir-
rhosis because there is “an increased risk of toxicity and 
consequent potential worsening of liver disease in patients 
in CTP Class B” [23].
Of course, this study has some limitations: no randomi-
sation, no calculation of sample size, laboratory tests not 
centralized, and no rigid protocol for the follow-up. How-
ever, this is what happens in clinical practice every day and 
this is the real strength of this study: to reproduce real life 
exactly. The other positive feature of this study is that the 
centres were selected by AISF and AIFA and they were all 
specialized centres for the treatment of liver diseases and in 
patients with a viral aetiology in particular.
In conclusion, as for the SVR12, the result was certainly 
very high, considering the population enrolled. It is encour-
aging that these data differ little from that obtained in the 
pivotal trials of the combination OBV/PTV/r + DSV + RBV. 
Also in real-life studies of this combination, the percentage 
of SVR12 was comparable to the results obtained from this 
study, and the correlation between this study and other real-
life studies is a solid indicator of the data reproducibility.
Moreover, these data demonstrate that the safety of the 
combination OBV/PTV/r + DSV + RBV in elderly patients 
with compensated cirrhosis is excellent and can be used 
in these patients. Obviously, we need, as for all the other 
DAAs, long-term follow-up for a definitive demonstration 
that SVR12 is a reliable surrogate marker of clinical out-
come and that these therapies are able to modify the natural 
history of elderly patients with advanced cirrhosis.
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